Nigel DaviesScientist at AstraZeneca
On joining AstraZeneca in 2008, Nigel had “CMC” responsibilities for a number of projects spanning Phase 1 to life-cycle management, having particular involvement in bioequivalence strategies and regulatory submissions for several now approved products.
Since transitioning to the Advanced Drug Delivery group in the Innovative Medicine early development function in 2014, Nigel has pioneered AstraZeneca’s efforts into the delivery of mRNA therapeutics as well as oral delivery of macromolecules resulting in a number of assets progressing from early pre-clinical evaluation to clinical testing.
Before joining AstraZeneca, Nigel had almost 20 years tenure in academia at Universities in New Zealand and Australia leading research groups focusing on developing novel delivery systems for macromolecules. Over the years in academia, Nigel secured >US$2.5 million in competitive research grants (as principle or co-investigator), supervised (to completion) 19 post-graduate students and authored/co-authored 2 book chapters and >70 peer-reviewed journal articles.
Nigel strives to combine his research and drug development experience to identify and develop novel systems and strategies (both internal and via external collaborations) to overcome the challenges associated with the delivery of macromolecules in order to advance AstraZeneca’s New Modalities portfolio.